BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29858091)

  • 1. Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells.
    Mencía Á; Chamorro C; Bonafont J; Duarte B; Holguin A; Illera N; Llames SG; Escámez MJ; Hausser I; Del Río M; Larcher F; Murillas R
    Mol Ther Nucleic Acids; 2018 Jun; 11():68-78. PubMed ID: 29858091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes.
    Chamorro C; Mencía A; Almarza D; Duarte B; Büning H; Sallach J; Hausser I; Del Río M; Larcher F; Murillas R
    Mol Ther Nucleic Acids; 2016 Apr; 5(4):e307. PubMed ID: 27045209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.
    Izmiryan A; Ganier C; Bovolenta M; Schmitt A; Mavilio F; Hovnanian A
    Mol Ther Nucleic Acids; 2018 Sep; 12():554-567. PubMed ID: 30195791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
    Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
    Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by
    García M; Bonafont J; Martínez-Palacios J; Xu R; Turchiano G; Svensson S; Thrasher AJ; Larcher F; Del Rio M; Hernández-Alcoceba R; Garín MI; Mencía Á; Murillas R
    Mol Ther Methods Clin Dev; 2022 Dec; 27():96-108. PubMed ID: 36212909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.
    Bonafont J; Mencía Á; García M; Torres R; Rodríguez S; Carretero M; Chacón-Solano E; Modamio-Høybjør S; Marinas L; León C; Escamez MJ; Hausser I; Del Río M; Murillas R; Larcher F
    Mol Ther; 2019 May; 27(5):986-998. PubMed ID: 30930113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of mutations of the type VII collagen gene (COL7A1) in recessive dystrophic epidermolysis bullosa mitis (M-RDEB) from three Korean patients.
    Ryoo YW; Kim BC; Lee KS
    J Dermatol Sci; 2001 Jun; 26(2):125-32. PubMed ID: 11378329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations.
    McGrath JA; Ashton GH; Mellerio JE; Salas-Alanis JC; Swensson O; McMillan JR; Eady RA
    J Invest Dermatol; 1999 Sep; 113(3):314-21. PubMed ID: 10469327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.
    Titeux M; Pendaries V; Zanta-Boussif MA; Décha A; Pironon N; Tonasso L; Mejia JE; Brice A; Danos O; Hovnanian A
    Mol Ther; 2010 Aug; 18(8):1509-18. PubMed ID: 20485266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
    Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
    J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
    Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
    J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells.
    Jacków J; Guo Z; Hansen C; Abaci HE; Doucet YS; Shin JU; Hayashi R; DeLorenzo D; Kabata Y; Shinkuma S; Salas-Alanis JC; Christiano AM
    Proc Natl Acad Sci U S A; 2019 Dec; 116(52):26846-26852. PubMed ID: 31818947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological correlations of compound heterozygous COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
    Dunnill MG; McGrath JA; Richards AJ; Christiano AM; Uitto J; Pope FM; Eady RA
    J Invest Dermatol; 1996 Aug; 107(2):171-7. PubMed ID: 8757758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratinocyte cell lines derived from severe generalized recessive epidermolysis bullosa patients carrying a highly recurrent COL7A1 homozygous mutation: models to assess cell and gene therapies in vitro and in vivo.
    Chamorro C; Almarza D; Duarte B; Llames SG; Murillas R; García M; Cigudosa JC; Espinosa-Hevia L; Escámez MJ; Mencía A; Meana A; García-Escudero R; Moro R; Conti CJ; Del Río M; Larcher F
    Exp Dermatol; 2013 Sep; 22(9):601-3. PubMed ID: 23947675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytosine Deaminase Base Editing to Restore
    Naso G; Gkazi SA; Georgiadis C; Jayarajan V; Jacków J; Fleck R; Allison L; Ogunbiyi OK; McGrath JA; Ilic D; Di WL; Petrova A; Qasim W
    JID Innov; 2023 May; 3(3):100191. PubMed ID: 37213713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.
    Turczynski S; Titeux M; Tonasso L; Décha A; Ishida-Yamamoto A; Hovnanian A
    J Invest Dermatol; 2016 Dec; 136(12):2387-2395. PubMed ID: 27498345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compound heterozygosity for a recessive glycine substitution and a splice site mutation in the COL7A1 gene causes an unusually mild form of localized recessive dystrophic epidermolysis bullosa.
    Terracina M; Posteraro P; Schubert M; Sonego G; Atzori F; Zambruno G; Bruckner-Tuderman L; Castiglia D
    J Invest Dermatol; 1998 Nov; 111(5):744-50. PubMed ID: 9804332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
    Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
    Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
    Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
    JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa.
    Wang X; Wang X; Li Y; A S; Qiu B; Bushmalyova A; He Z; Wang W; Lara-Sáez I
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101134. PubMed ID: 38027067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.